ACRV Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. (ACRV) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $31.0K.
Where they traded
Last open-market purchase: January 14, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Sell | 14,036 | $2.21 | $31.0K | 2,230,052 −0.6% of holding | |||
| 2 fills | Sell | 1,713 | $2.01 | $3.4K | 2,244,088 −0.1% of holding | ||
| Devroe Eric | Chief Operating Officer | Sell | 604 | $2.01 | $1.2K | 146,349 −0.4% of holding | |
| Gamelin Erick | Chief Development Officer | Sell | 400 | $2.01 | $804 | 52,592 −0.8% of holding | |
| Miller Mary | Chief Legal Officer | Sell | 185 | $2.01 | $372 | 82,009 −0.2% of holding | |
| Peterson Katharine | Chief Accounting Officer | Sell | 101 | $2.01 | $203 | 18,033 −0.6% of holding | |
| Levy Adam D. | Chief Financial Officer | Sell | 1,142 | $1.57 | $1.8K | 66,008 −1.7% of holding | |
| Miller Mary | Chief Legal Officer | Sell | 573 | $1.76 | $1.0K | 82,194 −0.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.